<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To investigate whether EGF receptor (EGFR) pathway mutations predicted response to monotherapy with panitumumab, an anti-EGFR monoclonal antibody, in a randomized phase III study of <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>EXPERIMENTAL DESIGN: Using massively parallel multigene sequencing, we analyzed 320 samples for 9 genes, with multigene sequence data from 288 (90%) samples </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: Mutation rates were: KRAS (45%), NRAS (5%), BRAF (7%), PIK3CA (9%), PTEN (6%), TP53 (60%), EGFR (1%), AKT1 (&lt;1%), and CTNNB1 (2%) </plain></SENT>
<SENT sid="3" pm="."><plain>In the randomized study and open-label extension, 22 of 138 (16%) <z:mp ids='MP_0002169'>wild-type</z:mp> KRAS (codons 12/13/61) patients versus 0 of 103 mutant KRAS (codons 12/13) patients had objective responses </plain></SENT>
<SENT sid="4" pm="."><plain>Of 6 mutant KRAS (codon 61) patients, 1 with a Q61H mutation achieved partial response during the extension </plain></SENT>
<SENT sid="5" pm="."><plain>Among <z:mp ids='MP_0002169'>wild-type</z:mp> KRAS (codons 12/13/61) patients, 0 of 9 patients with NRAS mutations, 0 of 13 with BRAF mutations, 2 of 10 with PIK3CA mutations, 1 of 9 with PTEN mutations, and 1 of 2 with CTNNB1 mutations responded to panitumumab </plain></SENT>
<SENT sid="6" pm="."><plain>No patients responded to best supportive care alone </plain></SENT>
<SENT sid="7" pm="."><plain>Panitumumab treatment was associated with longer progression-free survival (PFS) among <z:mp ids='MP_0002169'>wild-type</z:mp> KRAS (codons 12/13/61) patients [HR, 0.39; 95% confidence interval (CI), 0.28-0.56] </plain></SENT>
<SENT sid="8" pm="."><plain>Among <z:mp ids='MP_0002169'>wild-type</z:mp> KRAS patients, a treatment effect for PFS favoring panitumumab occurred in patients with <z:mp ids='MP_0002169'>wild-type</z:mp> NRAS (HR, 0.39; 95% CI, 0.27-0.56) and <z:mp ids='MP_0002169'>wild-type</z:mp> BRAF (HR, 0.37; 95% CI, 0.24-0.55) but not mutant NRAS (HR, 1.94; 95% CI, 0.44-8.44) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: These results show the feasibility and potential clinical use of next-generation sequencing for evaluating predictive biomarkers </plain></SENT>
<SENT sid="10" pm="."><plain>Clin <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Res; 19(7); 1902-12. Â©2012 AACR </plain></SENT>
</text></document>